Association of proangiogenic and profibrotic serum markers with lung function and quality of life in sarcoidosis

• Published in: PloS one Vol. 16; no. 2; p. e0247197
• Main Authors: Biener, L, Kruse, J, Tuleta, I, Pizarro, C, Kreuter, M, Birring, S S, Nickenig, G, Skowasch, D
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 22.02.2021; Public Library of Science (PLoS)
• Subjects: Angiogenesis; Biology and Life Sciences; Biopsy; Blood tests; Carbon monoxide; Cardiology; Care and treatment; Chronic obstructive pulmonary disease; Correlation analysis; Enzymes; Fibroblast growth factor 2; Health aspects; Hospitals; Impairment; Internal medicine; Lung diseases; Markers; Medicine; Medicine and Health Sciences; Patients; Platelet-derived growth factor; Properties; Pulmonary fibrosis; Quality of life; Questionnaires; Respiratory function; Sarcoidosis; Serum levels; Transforming growth factor-b1; Vascular endothelial growth factor; Germany
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0247197

Sarcoidosis is a systemic inflammatory granulomatous disease, frequently affecting the lung. If left untreated, it may end in lung fibrosis. Proangiogenic and profibrotic vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β1, fibroblast growth factor (FGF)-2 and platelet-derived growth factor (PDGF)-AB are a known therapeutical target in pulmonary fibrosing diseases, e.g. IPF, but there is no targeted therapy option for pulmonary fibrosis in sarcoidosis. The aim of our study was to determine the association of these markers' serum levels on lung function and the patients' quality of life in a long-term follow-up of sarcoidosis patients, to provide further information for finding targeted therapy options for pulmonary sarcoidosis. 54 patients with sarcoidosis underwent blood sampling, pulmonary function testing and answered the King's Brief Interstitial Lung Disease (K-BILD) questionnaire at baseline and at three-years follow-up. Serum levels of profibrotic and angiogenic markers were assessed at baseline by enzyme-linked immunosorbent assay. Between 2015 and 2018, 54 patients with biopsy proven sarcoidosis were enrolled. Throughout the observation period, there was a significant decrease in the diffusion capacity for carbon monoxide (DLCO) [%] (-6.5504 ± 13,39, p = 0.001) and forced expiratory volume in one second predicted (FEV1) [%] (-6.07 ± 12.09, p = 0.001). Patients with greater impairment of forced vital capacity (FVC) did have significantly higher serum levels of VEGF (p = 0.03) and PDGF-AB (p<0.001). The K-BILD questionnaire did not change significantly during follow-up. However, patients with worsening K-BILD scores did have significantly higher serum-levels of PDGF-AB (2.67 pg/ml ± 0.93 vs. 1.88 pg/ml ± 0.60, p = 0.004) at baseline, compared to those with unchanged or increasing K-BILD scores. Among patients with pulmonary sarcoidosis, baseline serum levels of VEGF and PDGF-AB were associated with pulmonary function impairment. Furthermore, PDGF-AB was associated with worsening K-BILD scores. No such association was observed for FGF-2 and TGF-ß1. VEGF and PDGF-AB may be possible prognostic and therapeutic targets in sarcoidosis as a fibrosing ILD beyond IPF.